Heilongjiang ZBD Pharmaceutical Co., Ltd.

XSSC:603567 Stock Report

Market Cap: CN¥10.9b

Heilongjiang ZBD Pharmaceutical Balance Sheet Health

Financial Health criteria checks 5/6

Heilongjiang ZBD Pharmaceutical has a total shareholder equity of CN¥8.2B and total debt of CN¥3.3B, which brings its debt-to-equity ratio to 40.5%. Its total assets and total liabilities are CN¥12.7B and CN¥4.5B respectively. Heilongjiang ZBD Pharmaceutical's EBIT is CN¥685.3M making its interest coverage ratio -3. It has cash and short-term investments of CN¥966.2M.

Key information

40.5%

Debt to equity ratio

CN¥3.34b

Debt

Interest coverage ratio-3x
CashCN¥966.16m
EquityCN¥8.25b
Total liabilitiesCN¥4.45b
Total assetsCN¥12.70b

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 603567's short term assets (CN¥7.5B) exceed its short term liabilities (CN¥2.8B).

Long Term Liabilities: 603567's short term assets (CN¥7.5B) exceed its long term liabilities (CN¥1.7B).


Debt to Equity History and Analysis

Debt Level: 603567's net debt to equity ratio (28.8%) is considered satisfactory.

Reducing Debt: 603567's debt to equity ratio has reduced from 46% to 40.5% over the past 5 years.

Debt Coverage: 603567's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: 603567 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies